GlassScriptPhysician profile
Edward Whitesides
NPI 1033104344
$7,835.35
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,064 · 2021: $1,652 · 2022: $2,490 · 2023: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,608.65 | 2019-2023 | Provenge |
| Astellas Pharma US INC | $1,368.34 | 2019-2023 | Veozah, Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $837.75 | 2019-2023 | Erleada |
| Pfizer INC. | $508.58 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.70 | 2019-2023 | |
| 180 Medical, INC. | $272.13 | 2019-2023 | Gentlecath, Cure Catheter |
| Myovant Sciences INC. | $241.67 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $229.89 | 2023 | Gemtesa, Orgovyx |
| Endo Pharmaceuticals INC. | $207.46 | 2019-2023 | Xiaflex |
| Merck Sharp & Dohme LLC | $198.96 | 2020-2022 | |
| Accord Healthcare, INC. | $180.91 | 2022-2023 | |
| Urovant Sciences INC | $159.49 | 2021-2022 | |
| Teleflex LLC | $126.94 | 2022-2023 | Urolift |
| Astrazeneca Pharmaceuticals LP | $126.10 | 2020-2023 | Lynparza |
| Blue Earth Diagnostics | $121.08 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Whitesides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.